Results 51 to 60 of about 94,936 (269)

Adenovirus-Mediated Sensitization to the Cytotoxic Drugs Docetaxel and Mitoxantrone Is Dependent on Regulatory Domains in the E1ACR1 Gene-Region [PDF]

open access: yes, 2012
Oncolytic adenoviruses have shown promising efficacy in clinical trials targeting prostate cancers that frequently develop resistance to all current therapies.
Halldén Gunnel   +36 more
core   +1 more source

Gabapentinoids‐duloxetine combination therapy for chronic pain: A mechanism oriented rational to bridge theoretical knowledge and real life setting

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Chronic pain represents a complex debilitating condition that extends beyond the protective function of physiological pain, often persisting as an independent disease entity. Chronic primary and secondary pain syndromes reflect a multifaceted continuum involving nociceptive, neuropathic and nociplastic mechanisms.
Stefania Nobili   +6 more
wiley   +1 more source

Study on the Metabolic Reprogramming of Lung Cancer Cells Regulated by Docetaxel Based on Metabolomics

open access: yesChinese Journal of Lung Cancer, 2019
Background and objective Docetaxel is a commonly used anti-tumor drug in clinic, especially as the first-line drug for advanced non-small cell lung cancer (NSCLC). However, the molecular mechanism of docetaxel against NSCLC is still unclear.
Haichao SUN   +4 more
doaj   +1 more source

Docetaxel Enhances the Expression of STING Protein in PC3 Cells, and cGAMP Attenuates this Effect

open access: yesNovelty in Biomedicine, 2020
Background: The stimulator of interferon genes (STING) agonist (cGAMP) kills the cancer cells through the activation of the innate immune system. PC3 cells are high in BTK and low in STING.
Shaghayegh Salimi   +5 more
doaj   +1 more source

Localized Prostate Cancer Therapy: Tumor Microenvironment‐Activated Spermine Hydrogel With Real‐Time Autonomous Fluorescence Sensing

open access: yesChemistry – A European Journal, EarlyView.
First tumor microenvironment (TME)‐responsive spermine‐loaded hydrogel with autonomous sensing for advanced local therapy of prostate cancer (PCa) is developed. Spermine can be released from the hydrogel to kill the prostate cancer cells specifically under acidic TME.
Ho‐Fai Chau   +12 more
wiley   +1 more source

"Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter trial" [PDF]

open access: yes, 2008
The dissertation is focused on the evaluation of a Docetaxel-based sequential regimen as adjuvant therapy of breast cancer. Docetaxel is among the most active chemotherapeutic agents for breast cancer.
Forestieri, Valeria
core   +1 more source

Predictors of Toxicity of Weekly Docetaxel in Chemotherapy-Treated Non- Small Cell Lung Cancers

open access: yes, 2011
Weekly docetaxel. seems to be safe and effective compared with traditional triweekly docetaxel. as a second-line treatment for non-small cell lung cancer. However, the risk factors for severe toxicity of weekly docetaxel in this group of patients are not
CHEN, JO-PAI;LO, YIN;YU, CHONG-JEN;HSU, CHIUN;SHIH, JIN-YUAN;YANG, CHIH-HSIN;YANG, CHIH- HSIN   +1 more
core   +1 more source

Purification, Fluorescent Labeling, and Detyrosination of Mammalian Cell Tubulin for Biochemical Assays

open access: yesCytoskeleton, EarlyView.
ABSTRACT Microtubules play essential roles in numerous cellular processes. All microtubules are built from the protein tubulin, yet individual microtubules can differ spatially and temporally due to their tubulin isotype composition and post‐translational modifications (PTMs).
Ezekiel C. Thomas   +5 more
wiley   +1 more source

A novel prognostic risk score associated with resistance to docetaxel chemotherapy for predicting biochemical recurrence-free survival in patients with prostate cancer

open access: yesDiscover Oncology
Objective To identify molecular clusters and develop a novel prognostic risk score associated with resistance to docetaxel chemotherapy for predicting biochemical recurrence free survival (BCRFS) and tumor immune microenvironment of prostate cancer (PCa).
Desheng Zhu   +3 more
doaj   +1 more source

Population Pharmacokinetics and Exposure‐Response Analyses to Support Cofetuzumab Pelidotin (ABBV‐647) Dose Optimization in Non‐Small Cell Lung Cancer Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Cofetuzumab pelidotin (Cofe‐P) is an anti‐protein tyrosine kinase 7 (PTK7) antibody‐drug conjugate (ADC) being investigated for the treatment of adults with PTK7‐expressing, recurrent non‐small cell lung cancer (NSCLC). The first‐in‐human (FIH) trial demonstrated tolerability of dosages ≤ 2.8 mg/kg once every 3 weeks (Q3W) and ≤ 3.2 mg/kg Q2W ...
Carla Biesdorf   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy